References and record
Every source the edition rests on, the publication record, the corrections log and the open record.
Содержание
- ·Edition home
- ·Executive summary
- 1Genomics is data infrastructure and a therapeutic frontier
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Individualised editing outpaces delivery systems
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- AМетодология
- BData appendix
- CReferences and record
- ·Complete edition, for print
C.144 sources
NR-CIT-1, editor first. A DOI is linked where the source has one; Nexus records carry a UNI once the catalogue allocates it (NS-1).
- 1US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy uses CRISPR/Cas9, Lyfgenia a lentiviral vector; patients 12 years and older). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
- 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 7
- 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 7
- 4Musunuru, K. et al., Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease, New England Journal of Medicine 2025 (abstract read through the Europe PMC record; one infant, two infusions at about 7 and 8 months of age). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 5, chapter 6
- 5Clinical Trials Arena (ed.), FDA unveils new pathway to usher bespoke therapies to market (trade press, 13 November 2025; describes the plausible mechanism pathway announced in a journal article by the FDA Commissioner and the CBER Director; secondary report, weak evidence). Clinical Trials Arena, London. Observation year 2025. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 5, chapter 6, chapter 8
- 6Vertex Pharmaceuticals (ed.), Vertex Reports First Quarter 2026 Financial Results (company press release read through a wire page; Casgevy revenue USD 42.9 million against USD 14.2 million; pediatric submission completed; company statement, weak evidence). Vertex, Boston. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
- 7Chetlapalli, K. et al., Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis, Blood 2026 (abstract read through the Europe PMC record; gene therapy access limited by cost and manufacturing capacity). American Society of Hematology, Washington. Observation year 2026. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
- 8Montano-Campos, J.F. et al., Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda context, Gene Therapy 2026 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2026. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 8
- 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 5, chapter 6, chapter 7
- 10Lek, A. et al., Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne Muscular Dystrophy, New England Journal of Medicine 2023 (abstract read through the Europe PMC record). Massachusetts Medical Society, Waltham. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 4, chapter 6
- 11Nurk, S. et al., The complete sequence of a human genome, Science 2022 (abstract read through the Europe PMC record; 3.055 billion base pairs; nearly 200 million base pairs of new sequence). American Association for the Advancement of Science, Washington. Observation year 2022. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
- 12Liao, W.-W. et al. (Human Pangenome Reference Consortium), A draft human pangenome reference, Nature 2023 (abstract read through the Europe PMC record; 47 phased diploid assemblies; 119 million base pairs added). Springer Nature, London. Observation year 2023. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
- 13National Human Genome Research Institute (ed.), The Cost of Sequencing a Human Genome (fact sheet page; method notes read; the cost values sit in graphs and a linked table that were not read; page updated 16 May 2023). NHGRI, Bethesda. Observation year 2023. Accessed 2026-11-03.
- 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 7, chapter 8
- 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 7, chapter 8
- 16UK Biobank Whole-Genome Sequencing Consortium, Whole-genome sequencing of 490,640 UK Biobank participants, Nature 2025 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
- 17All of Us Research Program Genomics Investigators, Genomic data in the All of Us Research Program, Nature 2024 (abstract read through the Europe PMC record; 245,388 genomes; 77% from communities under-represented in research). Springer Nature, London. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
- 18Fatumo, S. et al., A roadmap to increase diversity in genomic studies, Nature Medicine 2022 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2022. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6
- 19Sirugo, G., Williams, S.M. and Tishkoff, S.A., The Missing Diversity in Human Genetic Studies, Cell 2019 (abstract read through the Europe PMC record). Cell Press, Cambridge. Observation year 2019. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6
- 20Stephens, Z.D. et al., Big Data: Astronomical or Genomical?, PLOS Biology 2015 (abstract read through the Europe PMC record). Public Library of Science, San Francisco. Observation year 2015. Accessed 2026-11-03. Cited in chapter 6, chapter 8
- 21Grealey, J. et al., The Carbon Footprint of Bioinformatics, Molecular Biology and Evolution 2022 (abstract read through the Europe PMC record; a software upgrade cut one tool footprint by 73%). Oxford University Press, Oxford. Observation year 2022. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
- 22Lannelongue, L., Grealey, J. and Inouye, M., Green Algorithms: Quantifying the Carbon Footprint of Computation, Advanced Science 2021 (abstract read through the Europe PMC record). Wiley, Weinheim. Observation year 2021. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 6, chapter 8
- 23Brixi, G. et al., Genome modelling and design across all domains of life with Evo 2, bioRxiv preprint 2025 (abstract read through the Europe PMC record; trained on 9.3 trillion base pairs; not peer reviewed at the time of reading). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03. Cited in chapter 6, chapter 8
- 24Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 2012 (abstract read through the Europe PMC record). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-03. Cited in chapter 4, chapter 6
- 25Komor, A.C. et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature 2016 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2016. Accessed 2026-11-03. Cited in chapter 6
- 26Anzalone, A.V. et al., Search-and-replace genome editing without double-strand breaks or donor DNA, Nature 2019 (abstract read through the Europe PMC record). Springer Nature, London. Observation year 2019. Accessed 2026-11-03. Cited in chapter 6
- 27World Health Organization (ed.), Human genome editing: a framework for governance (technical document, 12 July 2021; companion recommendations published separately and not read). WHO, Geneva. Observation year 2021. Accessed 2026-11-03. Cited in the summary, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
- 28Royal Society (ed.), Statement from the Organising Committee of the Third International Summit on Human Genome Editing (8 March 2023; convened by the Royal Society, the Academy of Medical Sciences, the US National Academies and The World Academy of Sciences). Royal Society, London. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
- 29UK Parliament (ed.), Genetic Technology (Precision Breeding) Act 2023, 2023 c. 6 (contents page read; section texts not read). UK Parliament, London. Observation year 2023. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 6, chapter 8
- 30Latham and Watkins (ed.), BIOSECURE Act becomes law, limiting grants with biotechnology companies of concern (law-firm summary; enacted 18 December 2025 in the FY2026 NDAA; OMB list due by 18 December 2026; secondary source of a statute). Latham and Watkins, Los Angeles. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 4, chapter 6, chapter 8
- 31MedTech Dive (ed.), China to lift Illumina export ban (trade press, November 2025; listing in February 2025, import ban in March 2025, lift on 10 November 2025, instrument sales in China down 54% in the third quarter; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 8
- 32MedTech Dive (ed.), Anne Wojcicki bid to buy 23andMe in bankruptcy (trade press, 17 June 2025; USD 305 million bid against a USD 256 million bid; state objections; secondary report, weak evidence). Industry Dive, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 8
- 33US Bureau of Labor Statistics (ed.), Occupational Outlook Handbook: Genetic Counselors (about 4,200 jobs in 2025; median pay USD 100,040 in May 2025; 10% growth projected 2025 to 2035). BLS, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
- 34Genomics England (ed.), Generation Study: newborn genome sequencing (initiative page; 100,000 babies; more than 200 conditions; recruitment progress not stated). Genomics England, London. Observation year 2026. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
- 35Vertex Pharmaceuticals (ed.), Vertex Reports Fourth Quarter and Full Year 2025 Financial Results, Form 8-K exhibit 99.1, 12 February 2026 (company filing read; Casgevy revenue USD 115.8 million in 2025 and USD 10.0 million in 2024; 64 patients infused in 2025; company statement, weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-05.
- 36European Parliament and Council of the European Union (eds.), Regulation (EU) 2026/1388 of 17 June 2026 on plants obtained by certain new genomic techniques and their products, and amending Regulation (EU) 2017/625, Official Journal L series, 26 June 2026 (text read; enters into force on the twentieth day after publication; applies from 17 July 2028, with Articles 29 to 31 from 16 July 2026). Publications Office of the European Union, Luxembourg. Observation year 2026. Accessed 2026-11-05. Cited in chapter 3, chapter 4, chapter 6, chapter 8
- 37US Food and Drug Administration (ed.), Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, Federal Register 91 (37), notice 2026-03713, docket FDA-2026-D-1256, 25 February 2026 (notice read; the draft covers genome editing and RNA-based therapies; comments due 27 April 2026; the guidance text itself was not read). FDA, Silver Spring. Observation year 2026. Accessed 2026-11-05. Cited in chapter 4, chapter 6
- 38NPR (ed.), Judge OKs sale of 23andMe, and its trove of DNA data, to a nonprofit led by its founder, by J. Ruwitch, 30 June 2025 (story read through the syndicated copy on KPBS; TTAM Research Institute won with a USD 305 million bid after a USD 256 million Regeneron bid; several states opposed the sale). NPR, Washington. Observation year 2025. Accessed 2026-11-05. Cited in chapter 3, chapter 4, chapter 8
- 39Intellia Therapeutics, Inc. (ed.), Form 8-K of 27 January 2026 and Form 8-K exhibit 99.2 of 2 March 2026 (company filings read; the FDA imposed clinical holds on the MAGNITUDE and MAGNITUDE-2 trials on 29 October 2025 and removed them on 27 January 2026 for MAGNITUDE-2 and on 2 March 2026 for MAGNITUDE, with enhanced liver monitoring; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-05. Cited in chapter 2
- 40Ultima Genomics (ed.), Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris (press release, 24 February 2025, read through a wire copy; USD 0.24 per million reads, enabling the USD 80 genome; vendor evidence, weak). Ultima Genomics, Fremont. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2
- 41Council of Europe (ed.), Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), Oviedo, 4 April 1997 (text read in the official Spanish publication, Boletin Oficial del Estado BOE-A-1999-20638, 20 October 1999; in force since 1 December 1999; article 13 allows an intervention to modify the human genome only if it does not aim to modify the genome of descendants). Council of Europe, Strasbourg. Observation year 1997. Accessed 2026-11-05. Cited in chapter 4, chapter 6
- 42Lander, E.S. et al., Adopt a moratorium on heritable genome editing, Nature 567 (7747), 165 to 168, 2019 (record read via Crossref). Springer Nature, London. Observation year 2019. Accessed 2026-11-05. Cited in chapter 4, chapter 6
- 43International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 409 (6822), 860 to 921, 2001 (record read via Crossref). Springer Nature, London. Observation year 2001. Accessed 2026-11-05. Cited in chapter 6
- 44United States Congress (ed.), Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 122 Stat. 881, 21 May 2008 (enrolled text read; prohibits discrimination on the basis of genetic information in health insurance and employment). US Government Publishing Office, Washington. Observation year 2008. Accessed 2026-11-05. Cited in chapter 4, chapter 6
C.2Publication record
Публикация
- Название
- Exponential Technology Report 2026: Genomics and Gene Editing, Baseline Edition
- Серия
- Reports · Exponential Technology Series XT-05
- Выпуск
- Baseline Edition 2026 · inaugural annual
- Версия
- v1.0.0 · draft for stewardship review
- Publication ID
- NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
- Закрытие доказательной базы
- 30 September 2026
- Publication date
- Октябрь 2026
- DOI
- concept and version DOI at deposit
Издатель
- Официальный издатель
- The Global Centre for Risk and Innovation (GCRI), for the Nexus Consortium
- Место
- Toronto
- Редактор
- Saeed Valadbaygi, Chief Steward and Managing Editor
- Управляющие
- GCRI · technical truth · the Global Risks Forum (GRF) · public meaning · the Global Risks Alliance (GRA) · capital meaning
- Лицензия
- text CC BY 4.0; data on the terms of each source
- Copyright
- © 2026 GCRI · Nexus Consortium
- Язык
- English (en-GB) source edition
- Correspondence
- Registry correction pathway · editorial office
Colophon
- Формат
- A4 portrait · screen, print and archival PDF
- Typefaces
- Space Grotesk (display) · Geist (text) · IBM Plex Sans Italic (standfirsts) · IBM Plex Mono (data)
- Design standard
- Reports Foundational Edition, Volume I, Part VII
- Доступность
- tagged PDF and HTML targets; text alternatives for every figure
- Производство
- Reports editorial team, GCRI
Release path for this version
| Шаг | Что происходит | Когда |
|---|---|---|
| Проект | editorial self-check complete at evidence close | Октябрь 2026 |
| Steward review | five passes on the exact draft (keys T · M · F · N) | Q4 2026 |
| Утверждение | publication authority approves the exact digest | before release |
| Deposit | concept and version DOI minted; registry pointer set | at release |
| Преемственность | the 2027 genomics edition reports changes against this baseline | 2027 |
- Current version
- v1.0.0 draft, stewardship review
- Previous edition
- none, first edition of the series
- Next edition
- NR-XTECH-GENOMICS-GLOBAL-2027-v1.0.0
- Latest version
- resolve the concept DOI or the registry record
- Correction route
- Registry correction pathway
- Notice types
- erratum · addendum · supersession · withdrawal
C.3Журнал исправлений
0correction notices. No edition has been released yet, so none can be corrected; the log below lists each edition’s current version.
| Выпуск | Версия | Дата | Статус | Изменение | Уведомление |
|---|---|---|---|---|---|
| XT-05 | NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0 | Октябрь 2026 | Проект | Baseline Edition 2026, inaugural annual edition, | Нет |
Notice types: erratum, addendum, supersession, withdrawal. A correction is a new version with a published notice; the earlier version stays resolvable, and no edition is ever edited in silence.
C.4Открытая запись
This edition’s open record
- Publication ID
- NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE-v1.0.0
- Desk identifier and series alias
- NR-GCRI-XT-05-2026-BASELINE-v1.0.0 · NR-XTC-XT-05-2026-BL
- Collection
- NR-COL-2026-BASELINE (IsPartOf at deposit)
- DOI
- Concept and version DOI at deposit, on Zenodo with DataCite metadata
- Versions
- Each correction is a new version (isNewVersionOf); the concept DOI resolves to the latest
- Bundle
- RO-Crate 1.2 with CITATION.cff, CodeMeta and PROV-O provenance; a signed manifest
- Лицензия
- CC BY 4.0 (SPDX CC-BY-4.0) for original material; metadata CC0 1.0
Credit and identity
- ORCID
- Your iD in the deposit and the contribution record; DataCite can then add the work to your ORCID record
- ROR
- Your organisation by its ROR identifier, never by a typed name alone
- CRediT
- Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualisation, Writing, review and editing
- Учётная запись
- None needed to contribute; never a password
Find and follow
Search the open indexes for Genomics and Gene Editing; software is cited by its SWHID from Software Heritage, and a quantified scenario run is preregistered on OSF before it is run. Annotation is your choice: Hypothesis opens this page in its own viewer.
Mirrors and harvest
The DOI is canonical. At release each signed bundle is also given an IPFS content identifier and a bloxberg anchor as mirrors; both are listed in the record once they exist. Zenodo exposes every record over OAI-PMH, and reviews and endorsements can arrive through COAR Notify where the repository supports it.
{
"metadata": {
"resource_type": {
"id": "dataset"
},
"title": "Evidence on Genomics and Gene Editing for Nexus Reports",
"publication_date": "YYYY-MM-DD",
"creators": [
{
"person_or_org": {
"type": "personal",
"family_name": "Your family name",
"given_name": "Your given name",
"identifiers": [
{
"scheme": "orcid",
"identifier": "0000-0000-0000-0000"
}
]
},
"affiliations": [
{
"id": "ROR identifier of your organisation"
}
]
}
],
"description": "What it is, where its record is kept and how it bears on Exponential Technology Report 2026: Genomics and Gene Editing.",
"rights": [
{
"id": "cc-by-4.0"
}
],
"subjects": [
{
"subject": "Nexus Reports"
},
{
"subject": "Genomics and Gene Editing"
},
{
"subject": "Exponential Technology Report · XT-05"
}
],
"related_identifiers": [
{
"identifier": "https://therisk.global/nexus-reports/editions/xt-05/",
"scheme": "url",
"relation_type": {
"id": "issupplementto"
},
"resource_type": {
"id": "publication-report"
}
}
],
"version": "1.0.0"
},
"custom_fields": {},
"access": {
"record": "public",
"files": "public"
},
"files": {
"enabled": true
},
"parent": {
"communities": {
"default": "nexusreports"
}
}
}C.5Where this edition sits among the six pillars
Foundry seals the evidence and Universe tests it; Reports publishes it; Standards takes its corrections and Academy teaches from it.
- F03 Sealed observations and indicator series Foundry Sealed observations and indicator series behind a profile (closeout).
- F04 After-action and scenario findings for Universe After-action and scenario findings for chapters 10 and 13 (after action review).
- F05 National Portfolio movement for chapter Foundry National Portfolio movement for chapter 11 (after action review).
- Applied in editions Standards Nexus Standards: applied in editions.
- XT-05 edition Reports Genomics and Gene Editing 2026, published in every format with its sources, citation and corrections.
- F06 Method and correction findings as change Standards Method and correction findings as change proposals (correction).
- F12 Q4 synthesis informs the next-year Universe Q4 synthesis informs the next-year mandate (renewal).
- Taught in the open Academy Risk Academy: taught in the open.
What Foundry and Universe hand to this edition, and what it hands to Standards, Universe and Academy. From the programme spine; XT-05 is a drafted Baseline Edition, so these handoffs run from its first operational quarter.
| Передача | Between | What crosses, and when |
|---|---|---|
| F03 | Foundry to Reports | Sealed observations and indicator series behind a profile (closeout). |
| F04 | Universe to Reports | After-action and scenario findings for chapters 10 and 13 (after action review). |
| F05 | Foundry to Reports | National Portfolio movement for chapter 11 (after action review). |
| Ring | Nexus Standards to Reports | Nexus Standards: applied in editions. |
| F06 | Reports to Nexus Standards | Method and correction findings as change proposals (correction). |
| F12 | Reports to Universe | Q4 synthesis informs the next-year mandate (renewal). |
| Ring | Reports to Risk Academy | Risk Academy: taught in the open. |